2014: Dr. Novack continues his busy schedule

Dr. Novack’s presentations in 2014 include: FDA requirements for new drugs at Glaucoma 360 (Glaucoma Research Foundation), “Better Therapeutics in Glaucoma Through Drug Delivery” in the Innovator’s symposium at the American Society for Cataract & Refractive Surgery, and a Phase 2b study of AR-13324 in glaucoma and ocular hypertension at ARVO.

Dr. Novack continues to advise numerous companies on FDA interactions, including critical End of Phase 2 meetings, with frequent meetings with the FDA. Numerous investment firms have asked Dr. Novack’s advise on investments in innovative ophthalmic firms.

ARVO – Ft. Lauderdale

Dr. Novack was an invited speaker at the ARVO Annual Meeting in Fort Lauderdale in May 2012 at a symposium on Off Label Use. Panelists included leading academic and FDA experts.

Ophthalmic Drug Development International Panel

In 2011, Dr. Novack was invited to speak on ophthalmic drug development on several international panels which included senior FDA ophthalmic personnel. These were:

  • Ophthalmology Innovation Summit (Orlando, FL)
  • Glaucoma sub-specialty day at the American Academy of Ophthalmology (Orlando, FL
  • International Symposium on Ocular Pharmacology and Therapeutics (Vienna, Austria) www.isopt.net

He also participated in the first ophthalmology workshop of the European Medicines Agency (London, UK).